Principal Financial Group Inc. Trims Stock Position in Insulet Co. (NASDAQ:PODD)
Principal Financial Group Inc. trimmed its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 0.3% during the fourth quarter ...
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...
Insulet price target raised to $335 from $315 at Bernstein
Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.